Page 7 - Protein Sciences Segment News Today

Share this article Share this article MINNEAPOLIS, Feb. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2020. Second Quarter FY2021 Snapshot Second quarter organic revenue increased by 19% (21% reported) to $224.3 million and 15% (16% reported) in the first half of fiscal 2021 to $428.5 million.   GAAP EPS was $1.15 versus $3.02 one year ago primarily relating to a non-recurring gain of approximately ...

/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, February 2, 2021, at...

ScaleReady Launches With the Mission to Revolutionize T Cell Therapy Manufacturing ScaleReady Launches With the Mission to Revolutionize T Cell Therapy Manufacturing ScaleReady, a joint venture between Bio-Techne (NASDAQ: TECH), Fresenius Kabi, and Wilson Wolf, launches today. The new company brings together proven tools and technologies for cell culture, cell activation, gene editing, and cell processing from its founding partners. ScaleReady provides leading therapeutic developers with the...

ScaleReady Launches With the Mission to Revolutionize T Cell Therapy Manufacturing ScaleReady is a joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf ScaleReadys mission is to make the business of cell and gene therapy practical and viable by providing the most simple, scalable and versatile manufacturing platform in the industry ScaleReady will provide sales, marketing, and application support for customers globally ScaleReady, a joint venture between Bio-Techne (NASDAQ: TECH),...